HyundaiBio & NIH Develop Avian Flu Treatment
- Hyundai Bioscience is making strides in the fight against avian influenza.
- 제프티 has already completed Phase 1 clinical trials in South Korea for COVID-19 treatment.
- Centers for Disease Control and prevention (CDC) have issued repeated warnings about the increasing severity of highly pathogenic avian influenza.
Hyundai Bioscience and NIH Collaborate on Avian Flu Treatment
Table of Contents
- Hyundai Bioscience and NIH Collaborate on Avian Flu Treatment
- Hyundai Bioscience and Avian Flu Treatment: Your Questions answered
- What is Hyundai Bioscience doing to combat avian flu?
- What is 제프티 (XafTy)?
- How close is 제프티 (xafty) to being available as a treatment?
- Why is ther so much concern about avian flu?
- What is the NIH’s role in this project?
- Why is this collaboration between Hyundai Bioscience and the NIH vital?
- What are the key takeaways about Hyundai Bioscience’s work on avian flu?
- Where can I get more facts about Avian flu?
Hyundai Bioscience is making strides in the fight against avian influenza. On March 13, 2025, the company announced that the U.S. National Institutes of Health (NIH), through it’s national Institute of Allergy and Infectious diseases (NIAID), has approved animal efficacy testing for Hyundai Bio’s ‘XafTy’ ( 제프티) as a potential treatment for highly pathogenic avian influenza (H5N1), commonly known as bird flu.
Advancing Towards Clinical Trials
제프티 has already completed Phase 1 clinical trials in South Korea for COVID-19 treatment. If the NIAID animal studies demonstrate efficacy, Hyundai Bio’s 조류독감 치료제 could potentially skip Phase 1 trials and proceed directly to Phase 2. This expedited progress timeline could prove crucial in responding swiftly to a potential avian flu pandemic.
Global concerns Over Avian Flu
The World Health Organization (WHO) and the U.S. Centers for Disease Control and prevention (CDC) have issued repeated warnings about the increasing severity of highly pathogenic avian influenza. They suggest that large-scale human infection is only a matter of time. Originally prevalent in poultry such as chickens and ducks,avian flu has seen a recent surge in infections among mammals,including cattle,dogs,and cats,positioning it as a leading candidate for the “next pandemic.”
Rising Cases and Mortality rates
The United States, in particular, has experienced a heightened sense of crisis following consecutive cases of highly pathogenic avian influenza infections last year, and the report of the first death in january. The mortality rate associated with avian flu is alarmingly high, exceeding 50%.
NIH’s Global Treatment Development Project
With the NIH-NIAID’s approval for joint development, Hyundai Bio’s 제프티 is now officially included in the NIH’s global treatment development project aimed at addressing a potential avian flu pandemic. The active ingredient in 제프티, niclosamide, has already demonstrated antiviral efficacy against the avian flu virus in cell-based experiments.
Strategic Partnership for Pandemic Preparedness
According to a representative from Hyundai Bioscience, “Avian flu is a perilous virus with a mortality rate of over 50%, and the number of human cases has been rapidly increasing as last year, raising concerns about the ‘typical stages toward the next pandemic.'” The representative added, ”This joint development will serve as a turning point in diversifying our treatment portfolio in preparation for the next pandemic and establishing a global cooperation system with the NIH for pandemic response.”
Key Takeaways
- Hyundai Bioscience is collaborating with the NIH on an avian flu treatment.
- 제프티 shows promise for expedited clinical trials.
- Global health organizations are concerned about the spread of avian flu.
- The collaboration aims to diversify treatment options and establish a global response system.
Hyundai Bioscience and Avian Flu Treatment: Your Questions answered
This article addresses common questions regarding Hyundai Bioscience’s efforts to combat avian flu, including their collaboration with the NIH and the potential of their drug, 제프티 (XafTy).
What is Hyundai Bioscience doing to combat avian flu?
Hyundai Bioscience is collaborating with the U.S. national Institutes of Health (NIH) to develop 제프티 (XafTy) as a potential treatment for highly pathogenic avian influenza (H5N1), commonly known as bird flu. On March 13, 2025, the NIH, through its National Institute of Allergy and Infectious Diseases (NIAID), approved animal efficacy testing for the drug.
What is 제프티 (XafTy)?
제프티 (XafTy, also written as ‘XafTy’) is Hyundai Bio’s antiviral drug candidate being developed as a broad-spectrum antiviral. The active ingredient in 제프티 (XafTy), niclosamide, has demonstrated antiviral efficacy against the avian flu virus in cell-based experiments.
How close is 제프티 (xafty) to being available as a treatment?
제프티 (XafTy) has already completed Phase 1 clinical trials in south Korea for COVID-19 treatment. If the NIAID animal studies demonstrate efficacy against avian flu, 제프티 (XafTy) could possibly skip Phase 1 trials and proceed directly to Phase 2 for avian flu treatment. This could significantly expedite the availability of the drug.
Why is ther so much concern about avian flu?
Global health organizations like the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) have issued repeated warnings about the increasing severity of avian influenza, also known as bird flu. Key concerns include:
potential for Human Infection: Experts suggest that large-scale human infection is only a matter of time.
Spread to Mammals: Avian flu has seen a recent surge in infections among mammals, including cattle, dogs, and cats, increasing the risk of transmission to humans.
High Mortality Rate: The mortality rate associated with avian flu is alarmingly high, exceeding 50%.
Pandemic potential: Due to the factors above, avian flu is considered a leading candidate for the “next pandemic.”
What is the NIH’s role in this project?
The NIH-NIAID’s approval for joint growth means that 제프티 (XafTy) is now officially included in the NIH’s global treatment development project aimed at addressing a potential avian flu pandemic. This collaboration provides resources and expertise to accelerate the development and potential deployment of 제프티 (XafTy).
Why is this collaboration between Hyundai Bioscience and the NIH vital?
According to a representative from Hyundai Bioscience, this joint development will:
Diversify their treatment portfolio in preparation for the next pandemic.
Establish a global cooperation system with the NIH for pandemic response.
* Address the threat posed by avian flu, a virus with a high mortality rate.
What are the key takeaways about Hyundai Bioscience’s work on avian flu?
Here’s a summary of the key points discussed:
| Key Area | Details |
| ——————– | ——————————————————————————————————————————————————————– |
| Collaboration | Hyundai Bioscience is collaborating with the NIH (NIAID) to develop an avian flu treatment. |
| Drug potential | 제프티 (XafTy) shows promise for expedited clinical trials due to prior Phase 1 trials for COVID-19. |
| Global Concerns | Global health organizations are concerned about the spread of avian flu due to its potential for human infection, spread to mammals, and high mortality rate.|
| Strategic Aims | The collaboration aims to diversify treatment options and establish a global response system for future pandemics.|
| active Ingredient | Niclosamide, the active ingredient in 제프티 (XafTy), has demonstrated antiviral efficacy against avian flu in cell-based experiments. |
Where can I get more facts about Avian flu?
Consult with a healthcare professional and refer to the Centers for Disease Control (CDC) and the World Health Organization (WHO) for any health concerns or information.